Portfolio

Active Medtech Investments

We seek well-defined investment opportunities at all development stages - from early seed capital to expansion-stage financing

Learn More
About Us Investment Team What We Invest In Portfolio Contact
©2017 BioVentures Investors  

Cardiosolutions, Inc. is a development stage company focused on a novel alternative to open heart surgery to solve the problem of mitral and tricuspid valve regurgitation. The company is developing a pioneering technology, the Mitra-Spacer™, designed to deliver an implant that will provide a sealing surface for the leaflets of the mitral valve, thereby significantly reducing or eliminating mitral regurgitation (MR). The technology is also readily transferable to the tricuspid valve for those patients with untreated tricuspid regurgitation. The company’s goal is to provide a new therapeutic alternative delivered in a minimally invasive procedure for a wide range of patients of all ages who suffer from moderate to severe mitral and tricuspid regurgitation, including a portion of those who are currently in congestive heart failure. Its less invasive procedure has the potential to substantially reduce procedure time, expedite patient recovery and provide a less costly alternative to current treatment options.

www.cardiosolutionsinc.com

X  CLOSE

For over 2,000 years, suture repair has been the accepted method to surgically address tendon injuries. Despite advancements in biomaterials, operative techniques, and postoperative rehabilitation protocols, complications following suture repair of tends are still common. CoNextions Medical is dedicated to dramatically improving patient outcomes and the economics of tendon repair worldwide.

www.conextionsmed.com

X  CLOSE

Deep Vein Medical (“DVM”) is developing an implantable prosthetic vein valve which potentially offers the first true curative treatment for individuals suffering from chronic venous insufficiency. The valve is constructed using biocompatible materials and can be delivered using a minimally invasive catheter-based approach. The company has successfully completed its initial animal studies, and expects to commence human clinical trials outside the U.S. in 2017.

X  CLOSE

Endotronix, a digital health medtech company, is developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from advanced heart failure. The Cordella™ Heart Failure System includes a cloud-based disease-management system and a breakthrough implantable wireless pulmonary artery pressure sensor. The seamlessly integrated system enables proactive management and early detection of worsening heart failure, which promotes ongoing therapeutic interventions to improve quality of life, reduce hospital readmissions, and lower care costs.

www.endotronix.com

X  CLOSE

HydroCision, Inc. is focused on the commercialization of proprietary fluidjet technology. The Company’s primary focus is to improve surgical outcomes by adapting water jet technology to various medical applications. The Company has accomplished this by developing a proprietary method of controlling a hair-thin, supersonic stream of sterile saline while simultaneously enabling an accompanying Venturi suction system to cut and selectively remove tissue of various densities from a surgical site in a minimally invasive manner. Single use hand piece instruments have been specifically designed to hold, cut, sculpt, or ablate tissue faster and with higher precision than other surgical modalities enhancing clinical and economic outcomes in multiple fields of surgery. The Companies current market focus includes spine and sports medicine.

www.hydrocision.com

X  CLOSE

Locemia Solutions was a privately-held specialty pharma company located in Montreal. The company developed an innovative delivery system for glucagon to make severe hypoglycemia rescue as simple as a puff in the nose for insulin users worldwide. Locemia developed the drug-device combination through completion of Phase III studies. Eli Lilly purchased the company in 2015 and will commercialize the Locemia product.

www.locemia.com

X  CLOSE

POC Medical Systems has developed a versatile technology platform to rapidly screen for disease using a single drop of blood. Their PandoraCDx system, based on microfluidics and using a CD disk, can be performed for a few dollars per test, has a 15 minutes test-to-result time, has high accuracy, and is completely portable. The first application of their system is the MammoAlert product, a breast cancer screening tool currently being deployed in India where the screening rate is an anemic 3%. The company plans to initiate commercialization of this product in Asia in 2018 followed by other regions of world. Future applications include a screening test for myocardial infarction, cervical cancer, oral cancer, and an oncology panel.

www.pocmedicalsystems.com

X  CLOSE

Rachiotek LLC has developed the Stabilimax® Dynamic Spine Stabilization System, a biomechanically superior motion preserving device. Stabilimax provides stabilization of the spine at one level from L1-S1 in skeletally mature patients with moderate to severe functional impairment further to receiving decompression surgery for the treatment of central, lateral, or foraminal spinal stenosis. Stabilimax has a wealth of unique unblinded class 1 clinical data at a 5 year follow up proving predictable and successful clinical outcomes which address comprehensive improvements in pain and function in the absence of major device-related complications.

www.rachiotek.com

X  CLOSE

Verax Biomedical was founded upon the singular vision of detecting bacterial contamination in cells and tissues intended for transfusion and transplantation. Recognizing that bacteria pose a unique infectious challenge in these life giving tissues, the company realized this called for novel approaches to detection. Their patented Pan Genera Detection (PGD) technology enables them to produce rapid tests that allow users to detect and eliminate contaminated materials from their inventory prior to use. The first application of PGD technology is the Platelet PGD Test, an FDA cleared Safety Measure for the detection of bacterial contamination in human platelets.

www.veraxbiomedical.com

X  CLOSE